-
1
-
-
0042832397
-
Adult AIDS Clinical Trials Group Cardiovascular Subcommittee; HIV Medical Association of the Infectious Diseases Society of America. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America
-
Dube M, Stein J, Aberg J, et al; Adult AIDS Clinical Trials Group Cardiovascular Subcommittee; HIV Medical Association of the Infectious Diseases Society of America. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613-627.
-
(2003)
Clin Infect Dis
, vol.37
, pp. 613-627
-
-
Dube, M.1
Stein, J.2
Aberg, J.3
-
3
-
-
27944508736
-
High-risk dysmetabolism disorders associated with HAART treated HIV disease and reimbursement of lipid lowering drugs, in a clinical and a socio-economic perspective
-
Manfredi R. High-risk dysmetabolism disorders associated with HAART treated HIV disease and reimbursement of lipid lowering drugs, in a clinical and a socio-economic perspective. AIDS Rev. 2005; 7:155-160.
-
(2005)
AIDS Rev
, vol.7
, pp. 155-160
-
-
Manfredi, R.1
-
4
-
-
0038065609
-
Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: An index of atherogenicity?
-
Badiou S, Merle De Boever C, Dupuy AM, et al. Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity? Atherosclerosis. 2003;168:107-113.
-
(2003)
Atherosclerosis
, vol.168
, pp. 107-113
-
-
Badiou, S.1
Merle De Boever, C.2
Dupuy, A.M.3
-
5
-
-
0037126526
-
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
-
National Cholesterol Education Program NCEP
-
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation. 2002;106:3143-3421.
-
(2002)
Circulation
, vol.106
, pp. 3143-3421
-
-
-
6
-
-
27744566719
-
Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: An 8-week, randomized, double-blind, placebo-controlled study
-
Davidson MH, Bays H, Rhyne J, et al. Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study. Clin Tner. 2005;27:715-727.
-
(2005)
Clin Tner
, vol.27
, pp. 715-727
-
-
Davidson, M.H.1
Bays, H.2
Rhyne, J.3
-
7
-
-
33845625228
-
Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Studv A5148 Study Team
-
Dube MP, Wu JW, Aberg JA, et al. Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Studv A5148 Study Team. Antivir Ther. 2006;11:1081-1089.
-
(2006)
Antivir Ther
, vol.11
, pp. 1081-1089
-
-
Dube, M.P.1
Wu, J.W.2
Aberg, J.A.3
-
8
-
-
33847330109
-
Reduction in triglyceride level with N-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: A randomized prospective study
-
De Truchis P, Kirstetter M, Perier A, et al. Reduction in triglyceride level with N-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: a randomized prospective study. J Acquir Immune Defic Syndr. 2007;44:278-285.
-
(2007)
J Acquir Immune Defic Syndr
, vol.44
, pp. 278-285
-
-
De Truchis, P.1
Kirstetter, M.2
Perier, A.3
-
9
-
-
27644547395
-
Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia
-
Wohl DA, Tien HC, Busby M, et al. Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin Infect Dis. 2005;41:1498-1504.
-
(2005)
Clin Infect Dis
, vol.41
, pp. 1498-1504
-
-
Wohl, D.A.1
Tien, H.C.2
Busby, M.3
-
10
-
-
64149092750
-
Effect of a low dose of salmon oil on triglycerides and lipid parameters in HIV patients receiving a HAART regimen and having elevated serum triglyceride levels and total cholesterol/high density lipoprotein ratio
-
February 5-8, Denver. Abstract 756
-
Baril JG, Kovacs C, Trottier S, et al. Effect of a low dose of salmon oil on triglycerides and lipid parameters in HIV patients receiving a HAART regimen and having elevated serum triglyceride levels and total cholesterol/high density lipoprotein ratio. 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver. Abstract 756.
-
(2006)
13th Conference on Retroviruses and Opportunistic Infections
-
-
Baril, J.G.1
Kovacs, C.2
Trottier, S.3
-
11
-
-
0042262057
-
Difficulties in understanding the metabolic complications of acquired immune deficiency syndrome
-
Grunfeld C, Tien R Difficulties in understanding the metabolic complications of acquired immune deficiency syndrome. Clin Infect Dis. 2003;37(suppl 2): S43-S46.
-
(2003)
Clin Infect Dis
, vol.37
, Issue.SUPPL. 2
-
-
Grunfeld, C.1
Tien, R.2
-
12
-
-
0025872834
-
Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome
-
Grunfeld C, Kotler DP, Shigenaga JK, et al. Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med. 1991;90:154-162.
-
(1991)
Am J Med
, vol.90
, pp. 154-162
-
-
Grunfeld, C.1
Kotler, D.P.2
Shigenaga, J.K.3
-
13
-
-
0037000618
-
Increased serum interferon alpha in HIV-1 associated lipodystrophy syndrome
-
Christeff N, Melchior JC, De Truchis P, et al. Increased serum interferon alpha in HIV-1 associated lipodystrophy syndrome. Eur J Clin Invest. 2002;32: 43-50.
-
(2002)
Eur J Clin Invest
, vol.32
, pp. 43-50
-
-
Christeff, N.1
Melchior, J.C.2
De Truchis, P.3
-
14
-
-
0033583977
-
Diagnosis, prediction, and natural course of HIV-1 pro tease-inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus
-
Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 pro tease-inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus. Lancet. 1999;353:2093-2099.
-
(1999)
Lancet
, vol.353
, pp. 2093-2099
-
-
Carr, A.1
Samaras, K.2
Thorisdottir, A.3
-
15
-
-
0033040212
-
Hyperlipidemia under treatment with proteiase inhibitors
-
Segerer S, Bogner JR, Walli R, et al. Hyperlipidemia under treatment with proteiase inhibitors. Infection. 1999;27:77-81.
-
(1999)
Infection
, vol.27
, pp. 77-81
-
-
Segerer, S.1
Bogner, J.R.2
Walli, R.3
-
16
-
-
0242636456
-
Endothelial function in HIV-infected patients receiving protease inhibitor therapy: Does immune competence affect cardiovascular risk?
-
Nolan D, Watts GF, Herrmann SE, et al. Endothelial function in HIV-infected patients receiving protease inhibitor therapy: does immune competence affect cardiovascular risk? Q J Med. 2003;96:825-832.
-
(2003)
Q J Med
, vol.96
, pp. 825-832
-
-
Nolan, D.1
Watts, G.F.2
Herrmann, S.E.3
-
17
-
-
27744590942
-
Indinavir impairs endothelial function in healthy HIV-negative men
-
Shankar SS, Dube MP, Gorski JC, et al. Indinavir impairs endothelial function in healthy HIV-negative men. Am Heart J. 2005;150:933.
-
(2005)
Am Heart J
, vol.150
, pp. 933
-
-
Shankar, S.S.1
Dube, M.P.2
Gorski, J.C.3
-
19
-
-
25144511573
-
Mechanisms of lipid elevations associated with the treatment of patients with HIV infection
-
Piliero PJ. Mechanisms of lipid elevations associated with the treatment of patients with HIV infection. MedGenMed. 2003;5:1.
-
(2003)
MedGenMed
, vol.5
, pp. 1
-
-
Piliero, P.J.1
-
20
-
-
19644395095
-
Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India
-
Pujari SN, Dravid A, Naik E, et al. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr. 2005;39:199-202.
-
(2005)
J Acquir Immune Defic Syndr
, vol.39
, pp. 199-202
-
-
Pujari, S.N.1
Dravid, A.2
Naik, E.3
-
21
-
-
26844543445
-
Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides
-
Dube MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS. 2005;19:1807-1818.
-
(2005)
AIDS
, vol.19
, pp. 1807-1818
-
-
Dube, M.P.1
Parker, R.A.2
Tebas, P.3
-
22
-
-
34247630552
-
Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens
-
Anastos K, Lu D, Shi Q, et al. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr. 2007;45:34-42.
-
(2007)
J Acquir Immune Defic Syndr
, vol.45
, pp. 34-42
-
-
Anastos, K.1
Lu, D.2
Shi, Q.3
-
23
-
-
33746461336
-
Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine
-
van Leth F, Hall DB, Lange JM, Reiss P. Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine. HIV Med. 2006;7:347-350.
-
(2006)
HIV Med
, vol.7
, pp. 347-350
-
-
van Leth, F.1
Hall, D.B.2
Lange, J.M.3
Reiss, P.4
-
24
-
-
0006166138
-
Insulin resistance in HIV lipodystrophy syndrome
-
Hadigan C, Grinspoon S. Insulin resistance in HIV lipodystrophy syndrome. AIDS Clin Care. 2001; 13(2):1.
-
(2001)
AIDS Clin Care
, vol.13
, Issue.2
, pp. 1
-
-
Hadigan, C.1
Grinspoon, S.2
-
25
-
-
11344293751
-
Cardiovascular risk and body-fat abnormalities in HIV-infected adults
-
Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl j Med. 2005;352:48-62.
-
(2005)
N Engl j Med
, vol.352
, pp. 48-62
-
-
Grinspoon, S.1
Carr, A.2
-
26
-
-
30944431733
-
Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis
-
Fisher SD, Miller TL, Lipshultz SE. Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis. Atherosclerosis. 2006; 185:1-11.
-
(2006)
Atherosclerosis
, vol.185
, pp. 1-11
-
-
Fisher, S.D.1
Miller, T.L.2
Lipshultz, S.E.3
-
27
-
-
33749168002
-
The changing face of HIV care: Common things really are common
-
Aberg JA. The changing face of HIV care: common things really are common. Ann Intern Med. 2006;145:463-465.
-
(2006)
Ann Intern Med
, vol.145
, pp. 463-465
-
-
Aberg, J.A.1
-
28
-
-
33746233466
-
Cardiovascular disease in HIV infection
-
Sudano I, Spieker LE, Noll G, et al. Cardiovascular disease in HIV infection. Am Heart J. 2006;151: 1147-1155.
-
(2006)
Am Heart J
, vol.151
, pp. 1147-1155
-
-
Sudano, I.1
Spieker, L.E.2
Noll, G.3
-
29
-
-
20944443940
-
Hospitalization for coronary heart disease and myocardial infarction among Northern California men with HIV-1 infection: Additional follow-up
-
February 8-11, San Francisco. Poster
-
Klein D, Hurley L, Quesenberry C, Sidney S. Hospitalization for coronary heart disease and myocardial infarction among Northern California men with HIV-1 infection: additional follow-up. 11th Conference on Retroviruses and Opportunistic Infections; February 8-11,2004; San Francisco. Poster 739.
-
(2004)
11th Conference on Retroviruses and Opportunistic Infections
, pp. 739
-
-
Klein, D.1
Hurley, L.2
Quesenberry, C.3
Sidney, S.4
-
30
-
-
0345064200
-
-
Friis-Møller N, Sabin C, Weber R, et al; Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction [published correction appears in N Engl J Med. 2004;350:955]. N Engl J Med. 2003;349:1993-2003.
-
Friis-Møller N, Sabin C, Weber R, et al; Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction [published correction appears in N Engl J Med. 2004;350:955]. N Engl J Med. 2003;349:1993-2003.
-
-
-
-
32
-
-
33644895405
-
Functional and structural markers of atherosclerosis in human immunodeficiency virus-infected patients
-
van Wijk JP, de Koning EJ, Cabezas MC, et al. Functional and structural markers of atherosclerosis in human immunodeficiency virus-infected patients. J Am Coll Cardiol. 2006;47:1117-1123.
-
(2006)
J Am Coll Cardiol
, vol.47
, pp. 1117-1123
-
-
van Wijk, J.P.1
de Koning, E.J.2
Cabezas, M.C.3
-
33
-
-
33750730628
-
-
Endothelial dysfunction in HIV infection, 3:126-131
-
Cotter BR. Endothelial dysfunction in HIV infection. Curr HIV/AIDS Rep. 2006;3:126-131.
-
Curr HIV/AIDS Rep. 2006
-
-
Cotter, B.R.1
-
34
-
-
33748209571
-
Endothelial function in HIV-infected patients with low or mild cardiovascular risk
-
Blanco JJ, Garcia IS, Cerezo JG, et al. Endothelial function in HIV-infected patients with low or mild cardiovascular risk. J Antimicrob Chemother. 2006;58: 133-139.
-
(2006)
J Antimicrob Chemother
, vol.58
, pp. 133-139
-
-
Blanco, J.J.1
Garcia, I.S.2
Cerezo, J.G.3
-
35
-
-
33644919396
-
Cardiovascular risk in patients with human immunodeficiency virus infection: Incomplete data
-
Stein JH. Cardiovascular risk in patients with human immunodeficiency virus infection: incomplete data. J Am Coll Cardiol. 2006;47:1124-1125.
-
(2006)
J Am Coll Cardiol
, vol.47
, pp. 1124-1125
-
-
Stein, J.H.1
-
36
-
-
0037456351
-
Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection
-
Bozzette SA, Ake CF, Tarn HK, et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med. 2003;348:702-710.
-
(2003)
N Engl J Med
, vol.348
, pp. 702-710
-
-
Bozzette, S.A.1
Ake, C.F.2
Tarn, H.K.3
-
37
-
-
0242267026
-
-
Klein D, Hurley LB, Sidney S. Cardiovascular disease and HIV infection. N Engl J Med. 2003;349:1869-1870; author reply 1869-1870.
-
Klein D, Hurley LB, Sidney S. Cardiovascular disease and HIV infection. N Engl J Med. 2003;349:1869-1870; author reply 1869-1870.
-
-
-
-
38
-
-
0037456433
-
Cardiovascular risk factors and antiretroviral therapy
-
Kuritzkes DR, Currier J. Cardiovascular risk factors and antiretroviral therapy. N Engl J Med. 2003; 348:679-680.
-
(2003)
N Engl J Med
, vol.348
, pp. 679-680
-
-
Kuritzkes, D.R.1
Currier, J.2
-
39
-
-
33748886125
-
Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use
-
Kwong GP, Ghani AC, Rode RA, et al. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use. AIDS. 2006;20:1941-1950.
-
(2006)
AIDS
, vol.20
, pp. 1941-1950
-
-
Kwong, G.P.1
Ghani, A.C.2
Rode, R.A.3
-
40
-
-
0345357772
-
HIV infection and cardiovascular disease - is there really a link?
-
Sklar P, Masur H. HIV infection and cardiovascular disease - is there really a link? N Engl J Med. 2003;349:2065-2067.
-
(2003)
N Engl J Med
, vol.349
, pp. 2065-2067
-
-
Sklar, P.1
Masur, H.2
-
41
-
-
38349193415
-
Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis
-
In press
-
Lorenz MW, Stephan C, Harmjanz A, et al. Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis. In press.
-
Atherosclerosis
-
-
Lorenz, M.W.1
Stephan, C.2
Harmjanz, A.3
-
42
-
-
33751515147
-
-
+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296.
-
+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296.
-
-
-
-
43
-
-
0036596229
-
The significance of measuring non-HDL-cholesterol
-
Hirsch GA, Vaid N, Blumenthal RS. The significance of measuring non-HDL-cholesterol. Prev Cardiol. 2002;5:156-159.
-
(2002)
Prev Cardiol
, vol.5
, pp. 156-159
-
-
Hirsch, G.A.1
Vaid, N.2
Blumenthal, R.S.3
-
44
-
-
0002340211
-
Switching antiretroviral drugs for treatment of metabolic complications in HIV-1 infection: Summary of selected trials
-
Saag M, Powderly W, Schambelan M, et al. Switching antiretroviral drugs for treatment of metabolic complications in HIV-1 infection: summary of selected trials. Top HIV Med. 2002;10:47-51.
-
(2002)
Top HIV Med
, vol.10
, pp. 47-51
-
-
Saag, M.1
Powderly, W.2
Schambelan, M.3
-
45
-
-
64149111574
-
-
Parker R, Yang W, Wang S, et al. Transcriptional profiles support proteasome modulation hypothesis for lipid disturbances of current HIV-protease inhibitors and lipid neutrality of atazanavir. 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; July 8-11, 2003; Paris. Antivir Ther. 2003;8(4):L49. Abstract 68.
-
Parker R, Yang W, Wang S, et al. Transcriptional profiles support proteasome modulation hypothesis for lipid disturbances of current HIV-protease inhibitors and lipid neutrality of atazanavir. 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; July 8-11, 2003; Paris. Antivir Ther. 2003;8(4):L49. Abstract 68.
-
-
-
-
46
-
-
21844443541
-
Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment
-
Keiser PH, Sension MG, DeJesus E, et al. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment. BMC Infect Dis. 2005;5:2.
-
(2005)
BMC Infect Dis
, vol.5
, pp. 2
-
-
Keiser, P.H.1
Sension, M.G.2
DeJesus, E.3
-
47
-
-
0032903844
-
Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
-
Martinez E, Conget I, Lozano L, et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS. 1999;13:805-810.
-
(1999)
AIDS
, vol.13
, pp. 805-810
-
-
Martinez, E.1
Conget, I.2
Lozano, L.3
-
48
-
-
21844480420
-
Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia
-
Calza L, Manfredi R, Colangeli V, et al. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS. 2005;19:1051-1058.
-
(2005)
AIDS
, vol.19
, pp. 1051-1058
-
-
Calza, L.1
Manfredi, R.2
Colangeli, V.3
-
49
-
-
33746809138
-
Distribution, inter-conversion, and dose response of n-3 fatty acids in humans
-
Arterburn L, Hall E, Oken H. Distribution, inter-conversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr. 2006;83(suppl):1467S- 1476S.
-
(2006)
Am J Clin Nutr
, vol.83
, Issue.SUPPL.
-
-
Arterburn, L.1
Hall, E.2
Oken, H.3
-
50
-
-
0033954765
-
Polyunsaturaled fatty acids in the food chain in the United States
-
Kris-Etherton P, Taylor D, Yu-Poth S, et al. Polyunsaturaled fatty acids in the food chain in the United States. Am J Clin Nutr. 2000;71:179S-188S.
-
(2000)
Am J Clin Nutr
, vol.71
-
-
Kris-Etherton, P.1
Taylor, D.2
Yu-Poth, S.3
-
51
-
-
0030974010
-
n-3 Fatty acids and serum lipoproteins: Human studies
-
Harris WS. n-3 Fatty acids and serum lipoproteins: human studies. Am J Clin Nutr. 1997;65:1645S-1654S.
-
(1997)
Am J Clin Nutr
, vol.65
-
-
Harris, W.S.1
-
52
-
-
0031425356
-
Safety and efficacy of Omacor in severe hypertriglyceridemia
-
Harris WS, Ginsberg HN, Arunakul N, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk. 1997;4:385-391.
-
(1997)
J Cardiovasc Risk
, vol.4
, pp. 385-391
-
-
Harris, W.S.1
Ginsberg, H.N.2
Arunakul, N.3
-
53
-
-
1642528026
-
Fish oil supplementation: Evidence for health benefits
-
Harris WS. Fish oil supplementation: evidence for health benefits. Cleve Clin J Med. 2004;71:208-221.
-
(2004)
Cleve Clin J Med
, vol.71
, pp. 208-221
-
-
Harris, W.S.1
-
54
-
-
33746824712
-
n-3 Fatty acid dietary recommendations and food sources to achieve essentiality and cardiovascular benefits
-
Gebauer SK, Psota TL, Harris WS, Kris-Etherton PM. n-3 Fatty acid dietary recommendations and food sources to achieve essentiality and cardiovascular benefits. Am J Clin Nutr. 2006;83(6 suppl): 1526S-1535S.
-
(2006)
Am J Clin Nutr
, vol.83
, Issue.6 SUPPL.
-
-
Gebauer, S.K.1
Psota, T.L.2
Harris, W.S.3
Kris-Etherton, P.M.4
-
55
-
-
0037137299
-
American Heart Association Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease
-
Kris-Etherton PM, Harris WS, Appel LJ; American Heart Association Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106:2747-2757.
-
(2002)
Circulation
, vol.106
, pp. 2747-2757
-
-
Kris-Etherton, P.M.1
Harris, W.S.2
Appel, L.J.3
-
56
-
-
3042596046
-
Fish and shellfish as dietary sources of methylmercury and the omega-3 fatty acids, eicosahexaenoic acid and docosahexaenoic acid: Risks and benefits
-
Mahaffey KR. Fish and shellfish as dietary sources of methylmercury and the omega-3 fatty acids, eicosahexaenoic acid and docosahexaenoic acid: risks and benefits. Environ Res. 2004;95:414-428.
-
(2004)
Environ Res
, vol.95
, pp. 414-428
-
-
Mahaffey, K.R.1
-
57
-
-
64149100653
-
-
Omacor (omega-3 fatty acid ethyl esters) [prescribing information]. Liberty Corner, NJ: Reliant Pharmaceuticals, Inc; September 2005. Available at: http://www.omacorrx.com/OMACOR/OMACOR-Prescribing-Information.pdf. Accessed May 29, 2007.
-
Omacor (omega-3 fatty acid ethyl esters) [prescribing information]. Liberty Corner, NJ: Reliant Pharmaceuticals, Inc; September 2005. Available at: http://www.omacorrx.com/OMACOR/OMACOR-Prescribing-Information.pdf. Accessed May 29, 2007.
-
-
-
-
59
-
-
0038281520
-
Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance
-
Park Y, Harris WS. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J Lipid Res. 2003;44:455-463.
-
(2003)
J Lipid Res
, vol.44
, pp. 455-463
-
-
Park, Y.1
Harris, W.S.2
-
60
-
-
0036325388
-
Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia
-
Chan D, Watts G, Beilin L, et al. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes. 2002;51: 2377-2386.
-
(2002)
Diabetes
, vol.51
, pp. 2377-2386
-
-
Chan, D.1
Watts, G.2
Beilin, L.3
-
61
-
-
0036124659
-
N-3 polyunsaturated fatty acids in coronary heart disease: A meta-analysis of randomized controlled trials
-
Bucher H, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med. 2002;112:298-304.
-
(2002)
Am J Med
, vol.112
, pp. 298-304
-
-
Bucher, H.1
Hengstler, P.2
Schindler, C.3
Meier, G.4
-
62
-
-
2342518735
-
-
Balk E, Chung M, Lichtenstein A, et al. Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovascular disease. Evid Rep Technol Assess (Summ). Mar 2004:(93):l-6.
-
Balk E, Chung M, Lichtenstein A, et al. Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovascular disease. Evid Rep Technol Assess (Summ). Mar 2004:(93):l-6.
-
-
-
-
63
-
-
0024334111
-
Fish oils and plasma lipid and lipoprotein metabolism in humans: A critical review
-
63
-
63.Harris WS. Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. J Lipid Res. 1989;30:785-807.
-
(1989)
J Lipid Res
, vol.30
, pp. 785-807
-
-
Harris, W.S.1
-
64
-
-
0019253557
-
The effects of salmon oil upon plasma lipids, lipoproteins, and triglyceride clearance
-
Harris WS, Connor WE. The effects of salmon oil upon plasma lipids, lipoproteins, and triglyceride clearance. Trans Assoc Am Physicians. 1980;93:148-155.
-
(1980)
Trans Assoc Am Physicians
, vol.93
, pp. 148-155
-
-
Harris, W.S.1
Connor, W.E.2
-
65
-
-
0025948301
-
n-3 Fatty acid supplements reduce chylomicron levels in healthy volunteers
-
Harris W, Windsor S. n-3 Fatty acid supplements reduce chylomicron levels in healthy volunteers. J Atheroscler Tliromb. 1991;43:5-15.
-
(1991)
J Atheroscler Tliromb
, vol.43
, pp. 5-15
-
-
Harris, W.1
Windsor, S.2
-
66
-
-
0024244314
-
Reduction of postprandial triglyceridemia in humans by dietary n-3 fatty acids
-
Harris WS, Connor WE, Alam N, Illingworth DR. Reduction of postprandial triglyceridemia in humans by dietary n-3 fatty acids. J Lipid Res. 1988;29:1451-1460.
-
(1988)
J Lipid Res
, vol.29
, pp. 1451-1460
-
-
Harris, W.S.1
Connor, W.E.2
Alam, N.3
Illingworth, D.R.4
-
67
-
-
0024246814
-
Dietary polyunsaturated fats of the W-6 and W-3 series reduce postprandial lipoprotein levels. Chronic and acute effects of fat saturation on postprandial lipoprotein metabolism
-
Weintraub MS, Zechner R, Brown A, et al. Dietary polyunsaturated fats of the W-6 and W-3 series reduce postprandial lipoprotein levels. Chronic and acute effects of fat saturation on postprandial lipoprotein metabolism. J Clin Invest. 1988;82:1884-1893.
-
(1988)
J Clin Invest
, vol.82
, pp. 1884-1893
-
-
Weintraub, M.S.1
Zechner, R.2
Brown, A.3
-
68
-
-
0027104290
-
Effects of n-3 fatty acids on postprandial triacylglycerol and hormone concentrations in normal subjects
-
Williams CM, Moore F, Morgan L, Wright J. Effects of n-3 fatty acids on postprandial triacylglycerol and hormone concentrations in normal subjects. Br J Nutr. 1992;68:655-666.
-
(1992)
Br J Nutr
, vol.68
, pp. 655-666
-
-
Williams, C.M.1
Moore, F.2
Morgan, L.3
Wright, J.4
-
70
-
-
0034762548
-
An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia
-
Durrington P, Bhatnagar D, Mackness M, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart. 2001;85:544-548.
-
(2001)
Heart
, vol.85
, pp. 544-548
-
-
Durrington, P.1
Bhatnagar, D.2
Mackness, M.3
-
71
-
-
0037307248
-
Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity
-
Chan D, Watts G, Mori T, et al. Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity. Am J Clin Nutr. 2003;77:300-307.
-
(2003)
Am J Clin Nutr
, vol.77
, pp. 300-307
-
-
Chan, D.1
Watts, G.2
Mori, T.3
-
72
-
-
0033963643
-
Omacor in familial combined hyperlipidemia: Effects on lipids and low density lipoprotein subclasses
-
Calabresi L, Donati D, Pazzucconi F, et al. Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. Atherosclerosis. 2000;148:387-396.
-
(2000)
Atherosclerosis
, vol.148
, pp. 387-396
-
-
Calabresi, L.1
Donati, D.2
Pazzucconi, F.3
-
73
-
-
0032917836
-
Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins
-
Pownall HJ, Brauchi D, Kilinc C, et al. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis. 1999;143:285-297.
-
(1999)
Atherosclerosis
, vol.143
, pp. 285-297
-
-
Pownall, H.J.1
Brauchi, D.2
Kilinc, C.3
-
74
-
-
0031800499
-
The effects of an omega-3 ethyl ester concentrate on blood lipid concentrations in patients with hyperlipidaemia
-
Borthwick L. The effects of an omega-3 ethyl ester concentrate on blood lipid concentrations in patients with hyperlipidaemia. Clin Drug Invest. 1998;15:397-404.
-
(1998)
Clin Drug Invest
, vol.15
, pp. 397-404
-
-
Borthwick, L.1
-
75
-
-
0028555395
-
Effects of new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia
-
Mackness M, Bhatnagar D, Durrington P, et al. Effects of new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia. Eur J Clin Nutr. 1994;48:859-865.
-
(1994)
Eur J Clin Nutr
, vol.48
, pp. 859-865
-
-
Mackness, M.1
Bhatnagar, D.2
Durrington, P.3
-
76
-
-
0028960421
-
Improvement of serum lipids and blood pressure during intervention with n-3 fatty acids was not associated with changes in insulin levels in subjects with combined hyperlipidaemia
-
Grundt H, Nilsen DW, Hetland O, et al. Improvement of serum lipids and blood pressure during intervention with n-3 fatty acids was not associated with changes in insulin levels in subjects with combined hyperlipidaemia. J Intern Med. 1995;237:249-259.
-
(1995)
J Intern Med
, vol.237
, pp. 249-259
-
-
Grundt, H.1
Nilsen, D.W.2
Hetland, O.3
-
77
-
-
33947113384
-
Safety considerations with omega-3 fatty acid therapy
-
Bays HE. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol. 2007;99:35C-43C.
-
(2007)
Am J Cardiol
, vol.99
-
-
Bays, H.E.1
-
78
-
-
4444299083
-
Variable hypocoagulant effect of fish oil intake in humans: Modulation of fibrinogen level and thrombin generation (includes materials and methods addendum)
-
Vanschoonbeek K, Feijge M, Paquay M, et al. Variable hypocoagulant effect of fish oil intake in humans: modulation of fibrinogen level and thrombin generation (includes materials and methods addendum). Arterioscler Thromb Vase Biol. 2004;24:1734-1740.
-
(2004)
Arterioscler Thromb Vase Biol
, vol.24
, pp. 1734-1740
-
-
Vanschoonbeek, K.1
Feijge, M.2
Paquay, M.3
-
79
-
-
0031746608
-
Effects of marine fish oils on the anticoagulation status of patients receiving chronic warfarin therapy
-
Bender N, Kraynak M, Chiquette E, et al. Effects of marine fish oils on the anticoagulation status of patients receiving chronic warfarin therapy. J Thromb Thrombolysis. 1998;5:257-261.
-
(1998)
J Thromb Thrombolysis
, vol.5
, pp. 257-261
-
-
Bender, N.1
Kraynak, M.2
Chiquette, E.3
-
80
-
-
33745063941
-
Study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters
-
80
-
80.McKenney JM, Swearingen D, Di Spirito M, et al. Study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters. J Clin Pharmacol. 2006;46:785-791.
-
(2006)
J Clin Pharmacol
, vol.46
, pp. 785-791
-
-
McKenney, J.M.1
Swearingen, D.2
Di Spirito, M.3
-
81
-
-
0037040378
-
Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047
-
Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS. 2002;16:569-577.
-
(2002)
AIDS
, vol.16
, pp. 569-577
-
-
Fichtenbaum, C.J.1
Gerber, J.G.2
Rosenkranz, S.L.3
-
82
-
-
64149110156
-
Polyunsaturated ethyl esters of n-3 fatty acids in HTV-infected patients with moderate hypertriglyceridemia: Comparison with dietary and lifestyle changes, and fibrate therapy
-
Manfredi R, Calza L, Chiodo F. Polyunsaturated ethyl esters of n-3 fatty acids in HTV-infected patients with moderate hypertriglyceridemia: comparison with dietary and lifestyle changes, and fibrate therapy. J Cardiovasc Risk. 2004;36:876-881.
-
(2004)
J Cardiovasc Risk
, vol.36
, pp. 876-881
-
-
Manfredi, R.1
Calza, L.2
Chiodo, F.3
-
83
-
-
0035199219
-
Nutritional treatment for acquired immunodeficiency virus infection using an enterotropic peptide-based formula enriched with n-3 fatty acids: A randomized prospective trial
-
de Luis Roman DA, Bachiller P, Izaola O, et al. Nutritional treatment for acquired immunodeficiency virus infection using an enterotropic peptide-based formula enriched with n-3 fatty acids: a randomized prospective trial. Eur J Clin Nutr. 2001;55:1048-1052.
-
(2001)
Eur J Clin Nutr
, vol.55
, pp. 1048-1052
-
-
de Luis Roman, D.A.1
Bachiller, P.2
Izaola, O.3
-
84
-
-
33750854699
-
The safety and efficacy of fish oil in combination with fenofibrate in subjects on ART with hypertriglyceridemia who had an incomplete response to either agent alone: Results of ACTG A5186
-
February 5-8, Denver. Abstract 146
-
Gerber J, Kitch D, Aberg J, et al. The safety and efficacy of fish oil in combination with fenofibrate in subjects on ART with hypertriglyceridemia who had an incomplete response to either agent alone: results of ACTG A5186. 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver. Abstract 146.
-
(2006)
13th Conference on Retroviruses and Opportunistic Infections
-
-
Gerber, J.1
Kitch, D.2
Aberg, J.3
-
85
-
-
33749175714
-
Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City
-
Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med. 2006;145:397-406.
-
(2006)
Ann Intern Med
, vol.145
, pp. 397-406
-
-
Sackoff, J.E.1
Hanna, D.B.2
Pfeiffer, M.R.3
Torian, L.V.4
-
86
-
-
33751568894
-
Risk of cardiovascular disease in a cohort of HIV-infected adults: A study using carotid intima-media thickness and coronary artery calcium score
-
Mangili A, Gerrior J, Tang AM, et al. Risk of cardiovascular disease in a cohort of HIV-infected adults: a study using carotid intima-media thickness and coronary artery calcium score. Clin Infect Dis. 2006;43:1482-1489.
-
(2006)
Clin Infect Dis
, vol.43
, pp. 1482-1489
-
-
Mangili, A.1
Gerrior, J.2
Tang, A.M.3
-
87
-
-
33747122345
-
Metabolic and skeletal complications of HIV infection: The price of success
-
Morse CG, Kovacs JA. Metabolic and skeletal complications of HIV infection: the price of success. JAMA. 2006;296:844-854.
-
(2006)
JAMA
, vol.296
, pp. 844-854
-
-
Morse, C.G.1
Kovacs, J.A.2
|